Q-omics provides the consensus-scored SYNC profile across patient tissues and cancer cell-line models. SYNC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SYNC is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SYNC protein abundance shows 26,511 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, COAD, and LSCC as cancer lineages where SYNC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNC survival associations across molecular data types. SYNC RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNC RNA expression–survival associations across cancer types. High SYNC expression shows unfavorable associations in BLCA, MESO and LGG, but favorable associations in ESCA, UCS and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for SYNC RNA expression.
This table summarizes SYNC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SYNC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNC shows lower tumor expression in COAD, LUSC, LUAD, KIRC, BLCA and UCEC. The COAD box plot shows higher SYNC RNA expression in normal versus tumor tissue (log2 FC = −1.438, t-test p < 0.001).
This table shows molecular features associated with SYNC in patient tissues and cancer cell lines. In patient samples, SYNC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
